Human medicines European public assessment report EPAR Imraldi adalimumab Hidradenitis SuppurativaPsoriasisCrohn DiseaseUveitisArthritis RheumatoidArthritisColitis UlcerativeSpondylitis AnkylosingArthritis Psoriatic Date of authorisation

Human medicines European public assessment report EPAR Imraldi adalimumab Hidradenitis SuppurativaPsoriasisCrohn DiseaseUveitisArthritis RheumatoidArthritisColitis UlcerativeSpondylitis AnkylosingArthritis Psoriatic Date of authorisation 24082017 Revision ...